Trenibrorher@w:o - Novartis&Sirona?! Through further research and bringing together all the existing details in a way that is conclusive to me personally, I suspect that Novartis may have acquired a worldwide exclusive right to TFC-039.
In my view, this is supported by:
1. it is a promising compound, because otherwise Wangbang would not have continued to be interested and become a contracting party again after the premature termination and the findings of the clinical trial up to that point.
https://www.sironabiochem.com/sirona-biochem-signs-internati...
2. TFC-039 was already undergoing due diligence regarding new licensing opportunities at the time of the partnership agreement with Wangbang. (see link above)
3. non-disclosure agreement since 2019
https://www.sironabiochem.com/sirona-biochem-releases-ceo-le...
4. SGLT2-HEMMER as a possible new standard of care in combination therapy for immunoglobulin A nephropathy (IgAN)
https://www.sciencedirect.com/science/article/abs/pii/S00852...
5. Novartis recent M&A of Chinook Therapeutics and the potentially missing and complementary SGLT2-HEMMER in the context.
"The acquisition of Chinook adds two late-stage clinical programmes for IgAN..."
"Ownership of three IgAN programmes with different mechanisms of action would give Novartis the opportunity for a strong and broad position in IgAN, particularly as they all work in a non-immunosuppressive way, as well as the prospect of combination therapy for the disease."
https://pharmaphorum.com/news/novartis-builds-hefty-igan-pip...
So means there was already a 3rd IgAN programme.
6. no other significant news on TFC-039 since 2019.
7. sirona's latest tweet - There content is (quite comically) about acquiring agents related to IgAN therapy, in which SGLT2 HEMMERS are hugely important. Officially, of course, it says "The tweet is simply congratulating a Vancouver-based company on the recent deal.
We are also showcasing the talent here. Vancouver is growing as a biotech hub and attracting international pharmaceutical companies."
This is purely personal speculation! The content is neither a buy nor a sell recommendation!